Loading…
To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 9,698 other HR bills in the 117th — cohort avg 63d
This bill reauthorizes through FY2027 the Food and Drug Administration's Critical Path Public-Private Partnerships, which support medical product innovation, development, and safety.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2023 · fourth_quarter · Health Issues
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2022 (PL 117-103); Issues related to COVID 19 funding for BARDA; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169). S.4348. - FDASLA Act of 2022 (117th Congress), S.4535 - FDASRA Act of 2022 (117th Congress), H.R.7658 - To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships, provisions regarding reauthorization of FDA User Fee Programs (117th Congress); H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act.
Client expense: Not reported · Firm income: $50,000
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · third_quarter · Health Issues
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2022 (PL 117-103); Issues related to COVID 19 funding for BARDA; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169). S.4348. - FDASLA Act of 2022 (117th Congress), S.4535 - FDASRA Act of 2022 (117th Congress), H.R.7658 - To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships, provisions regarding reauthorization of FDA User Fee Programs (117th Congress).
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · second_quarter · Health Issues
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees; Issues related to the implementation of H.R.2471 - Consolidated Appropriations Act, 2022; Issues related to COVID 19 funding for BARDA; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169). S.4348. - FDASLA Act of 2022 (117th Congress), S.4535 - FDASRA Act of 2022 (117th Congress), H.R.7658 - To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships, provisions regarding reauthorization of FDA User Fee Programs (117th Congress).
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · first_quarter · Health Issues
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees; Issues related to the implementation of H.R.2471 - Consolidated Appropriations Act, 2022; Issues related to COVID 19 funding for BARDA; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169). S.4348. - FDASLA Act of 2022 (117th Congress), S.4535 - FDASRA Act of 2022 (117th Congress), H.R.7658 - To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships, provisions regarding reauthorization of FDA User Fee Programs (117th Congress).
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees; Issues related to H.R.2471 - Consolidated Appropriations Act, 2022; Issues related to COVID 19 funding for BARDA; Issues related to consideration and passage of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169). S.4348. - FDASLA Act of 2022, S.4535 - FDASRA Act of 2022, H.R.7658 - To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships, provisions regarding reauthorization of FDA User Fee Programs.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees; Issues related to H.R.2471 - Consolidated Appropriations Act, 2022; Issues related to COVID 19 funding for BARDA; Issues related to consideration and passage of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169). S.4348. - FDASLA Act of 2022, S.4535 - FDASRA Act of 2022, H.R.7658 - To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships, provisions regarding reauthorization of FDA User Fee Programs.
Client expense: Not reported · Firm income: $50,000
2022 · fourth_quarter · Health Issues
Issues related to prescription drug pricing reform legislation; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees, Issues related to Insulin pricing, Issues regarding the 340B Drug Pricing Program; Issues regarding the 2022 reauthorization of the Prescription Drug User Fee Act (PDUFA); Issues regarding Centers for Medicare and Medicaid Services draft National Coverage Decision (NCD) Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (CAG-00460N). Issues related to consideration and passage of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169); S.4348. - FDASLA Act of 2022, S.4535 - FDASRA Act of 2022, H.R.7658 - To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships, provisions regarding reauthorization of FDA User Fee Programs; Issues related to health care coverage and access to certain imaging diagnostics.
Client expense: Not reported · Firm income: $50,000
2022 · third_quarter · Health Issues
Issues related to prescription drug pricing reform legislation; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees, Issues related to Insulin pricing, Issues regarding the 340B Drug Pricing Program; Issues regarding the 2022 reauthorization of the Prescription Drug User Fee Act (PDUFA); Issues regarding Centers for Medicare and Medicaid Services draft National Coverage Decision (NCD) Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimers Disease (CAG-00460N). Issues related to consideration and passage of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169); S.4348. - FDASLA Act of 2022, S.4535 - FDASRA Act of 2022, H.R.7658 - To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships, provisions regarding reauthorization of FDA User Fee Programs.
Client expense: Not reported · Firm income: $50,000
2022 · third_quarter · Health Issues
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees; Issues related to H.R.2471 - Consolidated Appropriations Act, 2022; Issues related to COVID 19 funding for BARDA; Issues related to consideration and passage of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169). S.4348. - FDASLA Act of 2022, S.4535 - FDASRA Act of 2022, H.R.7658 - To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships, provisions regarding reauthorization of FDA User Fee Programs.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE